<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01810926</url>
  </required_header>
  <id_info>
    <org_study_id>OPBG_361.11</org_study_id>
    <secondary_id>2011-004730-34</secondary_id>
    <nct_id>NCT01810926</nct_id>
  </id_info>
  <brief_title>T&amp;B Depletion Non Malignant</brief_title>
  <official_title>A Phase II Multicentre, Randomized, Controlled Open-label Study on the Use of Anti-thymocyte Globulin and Rituximab for Immunomodulation of Graft-versus-host Disease in Allogeneic Matched Transplants for Non Malignancies</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Franco Locatelli</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Milano Bicocca</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>medac GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Fresenius AG</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Bambino Gesù Hospital and Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      • The primary aim of the present trial is to assess in a randomized fashion the benefit on
      standard graft-versus-host disease (GVHD) prophylaxis of the addition of ATG-Fresenius S ® in
      transplants from matched related donors (MRD) and of anti-CD20 rituximab in transplants from
      matched unrelated donors (MUD). Both safety and efficacy of the treatment will be assessed,
      in particular in respect to the clinical status of the patient, i.e. prevention of graft
      failure and chronic GvHD and of Ebstein Barr virus (EBV) viremia for MUD patients.

      The conditioning proposed combines myeloablative drugs with a favorable safety profile such
      as treosulfan, thiotepa (Tepadina®) and fludarabine with the intent to reduce the traditional
      immediate and late toxicity of busulfan and cyclophosphamide.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients transplanted from a MRD

      The primary end-point is the cumulative incidence of a combined end-point defined as the time
      from randomization to:

        -  primary and secondary graft failure,

        -  aGVHD II-IV,

        -  cGVHD,

        -  death, whichever occurs first.

      For patients transplanted from a MUD

      The primary end-point is the cumulative incidence of a combined end-point defined as the time
      from randomization to:

        -  aGVHD II-IV,

        -  EBV viremia, whichever occurs first.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <completion_date type="Anticipated">October 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2015</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Acute graft-versus-host disease (aGVHD) II-IV and chronic GvHD</measure>
    <time_frame>From date of randomization assessed up to 100 months</time_frame>
    <description>For patients transplanted from a MRD
The cumulative incidence of a combined end-point defined as the time from randomization to:
primary and secondary graft failure,
aGVHD II-IV,
cGVHD,
death, whichever occurs first.
For patients transplanted from a MUD
The cumulative incidence of a combined end-point defined as the time from randomization to:
aGVHD II-IV,
EBV viremia, whichever occurs first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Chronic graft-versus-host disease (cGVHD)</measure>
    <time_frame>From date of randomization assessed up to 100 months</time_frame>
    <description>The cumulative incidence and severity of cGVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Treatment related mortality (TRM)</measure>
    <time_frame>From date of randomization assessed up to 100 months</time_frame>
    <description>The incidence of TRM</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From date of randomization assessed up to 100 months</time_frame>
    <description>The overall survival probability</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">130</enrollment>
  <condition>Graft Versus Host Disease</condition>
  <arm_group>
    <arm_group_label>MRD-Regimen&amp;Polyclonal antibody</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients MRD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 &amp; ATG-Fresenius S® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MRD-Regimen</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients receiving stem cell transplantation from a matched related donors (MRD) will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²) + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 (total dose of 150 mg/m²) after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals (total dose of 8 mg/kg)+ Cyclosporine A iv at a starting dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL (In the absence of GvHD CSA will be tapered after day + 180 and stopped at 9-12 months) + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients MUD will be randomized to receive Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 &amp; Rituximab in a single infusion of 200 mg/m2 on day -1</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MUD-Regimen</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Patients MUD will be randomized to receive only Treosulfan iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 + Fludarabine iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan + Thiotepa iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals + Cyclosporine A iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL + Methotrexate iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11 + ATG-Fresenius S ® iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>polyclonal antibody</intervention_name>
    <description>iv at a dose of 5 mg/kg within 8 hours on day -4,-3,-2 (total dose 15 mg/kg)</description>
    <arm_group_label>MRD-Regimen&amp;Polyclonal antibody</arm_group_label>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <arm_group_label>MUD-Regimen</arm_group_label>
    <other_name>ATG S Fresenius</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>single infusion of200 mg/m2 on day -1</description>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <other_name>Mabthera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>iv at a dose of 14 g/m² within 120 minutes on day -7, - 6, -5 (total dose of 42 g/m²)</description>
    <arm_group_label>MRD-Regimen&amp;Polyclonal antibody</arm_group_label>
    <arm_group_label>MRD-Regimen</arm_group_label>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <arm_group_label>MUD-Regimen</arm_group_label>
    <other_name>Medac</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine</intervention_name>
    <description>iv at a dose of 30 mg/ m² within 30 minutes on day -7, -6, -5,-4,-3 after treosulfan</description>
    <arm_group_label>MRD-Regimen&amp;Polyclonal antibody</arm_group_label>
    <arm_group_label>MRD-Regimen</arm_group_label>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <arm_group_label>MUD-Regimen</arm_group_label>
    <other_name>Fludara</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>iv at a dose of 8 mg/kg on day - 3 divided into 2 infusions at 12 hrs intervals</description>
    <arm_group_label>MRD-Regimen&amp;Polyclonal antibody</arm_group_label>
    <arm_group_label>MRD-Regimen</arm_group_label>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <arm_group_label>MUD-Regimen</arm_group_label>
    <other_name>Tepadina</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cyclosporine A</intervention_name>
    <description>iv at a dose of 3 mg/kg/day starting from day -1 and a dose adjustment will be done to obtain plasma levels of 150-250 ng/mL</description>
    <arm_group_label>MRD-Regimen&amp;Polyclonal antibody</arm_group_label>
    <arm_group_label>MRD-Regimen</arm_group_label>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <arm_group_label>MUD-Regimen</arm_group_label>
    <other_name>Neoral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6</description>
    <arm_group_label>MRD-Regimen&amp;Polyclonal antibody</arm_group_label>
    <arm_group_label>MRD-Regimen</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <description>iv at a dose of 15 mg/m2 on day +1, at a dose of 10 mg/m2 on day + 3 and + 6 and at a dose of 10 mg/m2 on day +11</description>
    <arm_group_label>MUD-Regimen &amp; Rituximab</arm_group_label>
    <arm_group_label>MUD-Regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  non malignant haematological and inherited metabolic disorders benefiting from an
             allogeneic HSCT conditioned with a myeloablative regimen

          -  Availability of a matched related donor (MRD) or Matched Unrelated Donor (MUD)

          -  Lansky or Karnofsky Index ≥ 60

          -  Inherited metabolic disorders: DQ ≥ 70 (+ MRI Loes score ≤ 9 for adrenoleukodystrophy)

          -  Adequate cardiac, renal, hepatic and pulmonary functions as evidenced by:

          -  Serum creatinine ≤ 1.5 × upper limit of normal (ULN)

          -  Heart shortening fraction (left-ventricle) &gt; 28 % or LVEF &gt; 55%

          -  Serum bilirubin ≤ 1.5 × ULN (except for Wolman disease),

          -  AST and ALT ≤ 2.5 × ULN (except for thalassemic syndromes and Wolman disease)

          -  Pulmonary function: if cooperative: FEV1 and FVC on pulmonary function testing &gt; 60 %;
             if non cooperative: pulse oximetry &gt; 95 % in room air

          -  Availability of autologous back up marrow (&gt; 2 x 108 TNC+ cells/kg or &gt; 2 x 106 CD34+
             cells/kg) for MUD

          -  Adequate contraception in female patients of child-bearing potential

          -  Signed informed consent

        Exclusion Criteria:

          -  Any malignancy

          -  Liver cirrhosis evidenced on liver histology (performed in suspicious cases or in case
             of Wolman disease)

          -  HIV- positivity

          -  Clinically significant pleural effusion or ascites

          -  Pregnancy or lactation

          -  Known hypersensitivity to trial drugs

          -  Participation in another experimental drug trial in the 2 months preceding enrollment

          -  Non-cooperative behaviour or non-compliance

          -  Previous HSCT
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Franco Locatelli, Prof</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bambino Gesù Hospital and Research Institute</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Cagliari</name>
      <address>
        <city>Cagliari</city>
        <zip>09126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>San Raffaele Scientific Institute</name>
      <address>
        <city>Milano</city>
        <zip>20132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>University of Milano-Bicocca San Gerardo Hospital</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Bambino Gesù Hospital and Research Institute</name>
      <address>
        <city>Rome</city>
        <zip>00165</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Maria Ester Bernardo, MD</last_name>
      <email>mebernardo@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Franco Locatelli</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Bacigalupo A, Lamparelli T, Barisione G, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Sacchi N, van Lint MT, Bosi A; Gruppo Italiano Trapianti Midollo Osseo (GITMO). Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant. 2006 May;12(5):560-5.</citation>
    <PMID>16635791</PMID>
  </reference>
  <reference>
    <citation>Bacigalupo A, Lamparelli T, Bruzzi P, Guidi S, Alessandrino PE, di Bartolomeo P, Oneto R, Bruno B, Barbanti M, Sacchi N, Van Lint MT, Bosi A. Antithymocyte globulin for graft-versus-host disease prophylaxis in transplants from unrelated donors: 2 randomized studies from Gruppo Italiano Trapianti Midollo Osseo (GITMO). Blood. 2001 Nov 15;98(10):2942-7.</citation>
    <PMID>11698275</PMID>
  </reference>
  <reference>
    <citation>Ballet JJ, Griscelli C, Coutris C, Milhaud G, Maroteaux P. Bone-marrow transplantation in osteopetrosis. Lancet. 1977 Nov 26;2(8048):1137.</citation>
    <PMID>73050</PMID>
  </reference>
  <reference>
    <citation>Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, Egeler M, Lankester AC, Egberts AC, Zwaveling J, Boelens JJ. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant. 2009 Feb;15(2):231-41. doi: 10.1016/j.bbmt.2008.11.022.</citation>
    <PMID>19167683</PMID>
  </reference>
  <reference>
    <citation>Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van Kesteren C, Bierings M, Rademaker CM, den Hartigh J, Uiterwaal CS, Zwaveling J, Boelens JJ. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant. 2008 Jan;14(1):88-98.</citation>
    <PMID>18158965</PMID>
  </reference>
  <reference>
    <citation>Basara N, Baurmann H, Kolbe K, Yaman A, Labopin M, Burchardt A, Huber C, Fauser AA, Schwerdtfeger R. Antithymocyte globulin for the prevention of graft-versus-host disease after unrelated hematopoietic stem cell transplantation for acute myeloid leukemia: results from the multicenter German cooperative study group. Bone Marrow Transplant. 2005 May;35(10):1011-8.</citation>
    <PMID>15821768</PMID>
  </reference>
  <reference>
    <citation>Bernardo ME, Zecca M, Piras E, Vacca A, Giorgiani G, Cugno C, Caocci G, Comoli P, Mastronuzzi A, Merli P, La Nasa G, Locatelli F. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in patients with thalassaemia major. Br J Haematol. 2008 Nov;143(4):548-51. doi: 10.1111/j.1365-2141.2008.07385.x.</citation>
    <PMID>18986389</PMID>
  </reference>
  <reference>
    <citation>Bernaudin F, Socie G, Kuentz M, Chevret S, Duval M, Bertrand Y, Vannier JP, Yakouben K, Thuret I, Bordigoni P, Fischer A, Lutz P, Stephan JL, Dhedin N, Plouvier E, Margueritte G, Bories D, Verlhac S, Esperou H, Coic L, Vernant JP, Gluckman E; SFGM-TC. Long-term results of related myeloablative stem-cell transplantation to cure sickle cell disease. Blood. 2007 Oct 1;110(7):2749-56. Epub 2007 Jul 2.</citation>
    <PMID>17606762</PMID>
  </reference>
  <reference>
    <citation>Chiesa R, Cappelli B, Crocchiolo R, Frugnoli I, Biral E, Noè A, Evangelio C, Fossati M, Roccia T, Biffi A, Finizio V, Aiuti A, Broglia M, Bartoli A, Ciceri F, Roncarolo MG, Marktel S. Unpredictability of intravenous busulfan pharmacokinetics in children undergoing hematopoietic stem cell transplantation for advanced beta thalassemia: limited toxicity with a dose-adjustment policy. Biol Blood Marrow Transplant. 2010 May;16(5):622-8. doi: 10.1016/j.bbmt.2009.11.024. Epub 2009 Dec 4.</citation>
    <PMID>19963071</PMID>
  </reference>
  <verification_date>March 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 16, 2012</study_first_submitted>
  <study_first_submitted_qc>March 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 14, 2013</study_first_posted>
  <last_update_submitted>March 12, 2013</last_update_submitted>
  <last_update_submitted_qc>March 12, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 14, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bambino Gesù Hospital and Research Institute</investigator_affiliation>
    <investigator_full_name>Franco Locatelli</investigator_full_name>
    <investigator_title>Director Department of Pediatric Hematology and Oncology</investigator_title>
  </responsible_party>
  <keyword>indication for HSCT</keyword>
  <keyword>matched related donor</keyword>
  <keyword>MRD</keyword>
  <keyword>Matched Unrelated Donor</keyword>
  <keyword>MUD</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antibodies</mesh_term>
    <mesh_term>Immunoglobulins</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

